Tools and resources | Lung cancer: diagnosis and management | Guidance | NICE

Tools and resources

Tools to help you put the guidance into practice.

Summary versions

Treatment pathways
interactive PDF of all treatment pathways for squamous and non-squamous advanced non-small-cell lung cancer ^{PDF 719 KB} 11 August 2022
Squamous pathway: No targetable mutations, PD-L1 less than 50% ^{PDF 76 KB} 11 August 2022
Squamous pathway: No targetable mutations, PD-L1 50% or more ^{PDF 116 KB} 11 August 2022
Squamous pathway: RET fusion positive, PD-L1 less than 50% ^{PDF 80 KB} 11 August 2022
Squamous pathway: RET fusion positive, PD-L1 50% or more ^{PDF 119 KB} 11 August 2022
Squamous pathway: NTRK fusion positive, PD-L1 less than 50% ^{PDF 80 KB} 11 August 2022
Squamous pathway: NTRK fusion positive, PD-L1 50% or more ^{PDF 118 KB} 11 August 2022
Squamous pathway: KRAS G12C positive, PD-L1 less than 50% ^{PDF 81 KB} 11 August 2022
Squamous pathway: KRAS G12C positive, PD-L1 50% or more ^{PDF 119 KB} 11 August 2022
Non-squamous pathway: No targetable mutations, PD-L1 less than 50% ^{PDF 72 KB} 11 August 2022
Non-squamous pathway: No targetable mutations, PD-L1 50% or more ^{PDF 88 KB} 11 August 2022
Non-squamous pathway: EGFR-TK positive ^{PDF 105 KB} 11 August 2022
Non-squamous pathway: ALK positive ^{PDF 73 KB} 11 August 2022
Non-squamous pathway: ROS-1 positive ^{PDF 81 KB} 11 August 2022
Non-squamous pathway: RET fusion positive, PD-L1 less than 50% ^{PDF 84 KB} 11 August 2022
Non-squamous pathway: RET fusion positive, PD-L1 50% or more ^{PDF 100 KB} 11 August 2022
Non-squamous pathway: NTRK fusion positive, PD-L1 less than 50% ^{PDF 85 KB} 11 August 2022
Non-squamous pathway: NTRK fusion positive, PD-L1 50% or more ^{PDF 101 KB} 11 August 2022
Non-squamous pathway: KRAS G12C positive, PD-L1 less than 50% ^{PDF 85 KB} 11 August 2022
Non-squamous pathway: KRAS G12C positive, PD-L1 50% or more ^{PDF 100 KB} 11 August 2022
Fully accessible Word version of all treatment pathways for squamous and non-squamous advanced non-small-cell lung cancer ^{Word 46 KB} 11 August 2022
Squamous fully accessible summary: No targetable mutations, PD-L1 less than 50% ^{Word 32 KB} 11 August 2022
Squamous fully accessible summary: No targetable mutations, PD-L1 50% or more ^{Word 32 KB} 11 August 2022
Squamous fully accessible summary: RET fusion positive, PD-L1 less than 50% ^{Word 33 KB} 11 August 2022
Squamous fully accessible summary: RET fusion positive, PD-L1 50% or more ^{Word 32 KB} 11 August 2022
Squamous fully accessible summary: NTRK fusion positive, PD-L1 less than 50% ^{Word 33 KB} 11 August 2022
Squamous fully accessible summary: NTRK fusion positive, PD-L1 50% or more ^{Word 32 KB} 11 August 2022
Squamous fully accessible summary: KRAS G12C positive, PD-L1 less than 50% ^{Word 33 KB} 11 August 2022
Squamous fully accessible summary: KRAS G12C positive, PD-L1 50% or more ^{Word 33 KB} 11 August 2022
Non-squamous fully accessible summary: No targetable mutations, PD-L1 less than 50% ^{Word 33 KB} 11 August 2022
Non-squamous fully accessible summary: No targetable mutations, PD-L1 50% or more ^{Word 32 KB} 11 August 2022
Non-squamous fully accessible summary: EGFR-TK positive ^{Word 33 KB} 11 August 2022
Non-squamous fully accessible summary: ALK positive ^{Word 33 KB} 11 August 2022
Non-squamous fully accessible summary: ROS-1 positive ^{Word 33 KB} 11 August 2022
Non-squamous fully accessible summary: RET fusion positive, PD-L1 less than 50% ^{Word 33 KB} 11 August 2022
Non-squamous fully accessible summary: RET fusion positive, PD-L1 50% or more ^{Word 33 KB} 11 August 2022
Non-squamous fully accessible summary: NTRK fusion positive, PD-L1 less than 50% ^{Word 33 KB} 11 August 2022
Non-squamous fully accessible summary: NTRK fusion positive, PD-L1 50% or more ^{Word 33 KB} 11 August 2022
Non-squamous fully accessible summary: KRAS G12C positive, PD-L1 less than 50% ^{Word 33 KB} 11 August 2022
Non-squamous fully accessible summary: KRAS G12C positive, PD-L1 50% or more ^{Word 33 KB} 11 August 2022
Algorithm for intrathoracic staging before radical treatment ^{PDF 104 KB} 28 March 2019

Implementation support

Resource impact

Resource impact statement

Audit and service improvement

Baseline assessment tool ^{Excel 432 KB} 28 March 2019

Related news

Promising lung cancer treatment approved for Cancer Drugs Fund

Research recommendations

Research recommendations information

Guidance into practice